<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: risks could materially", fill: "#8b0000"},
{source: "3: risks could materially", target: "3: adversely affect", fill: "#8b0000"},
{source: "3: adversely affect", target: "3: financial condition", fill: "#8b0000"},
{source: "3: financial condition", target: "3: cash flows", fill: "#8b0000"},
{source: "3: risks could materially", target: "6: numerous difficulties", fill: "#ffff31"},
{source: "6: numerous difficulties", target: "6: commercializing", fill: "#ffff31"},
{source: "6: commercializing", target: "6: new products", fill: "#ffff31"},
{source: "6: new products", target: "6: manufacturing products", fill: "#ffff31"},
{source: "6: manufacturing products", target: "6: compliance with", fill: "#ffff31"},
{source: "6: compliance with", target: "6: regulatory standards", fill: "#ffff31"},
{source: "6: regulatory standards", target: "6: requisite regulatory approvals", fill: "#ffff31"},
{source: "6: requisite regulatory approvals", target: "6: such products", fill: "#ffff31"},
{source: "6: such products", target: "6: availability on commercially reasonable terms", fill: "#ffff31"},
{source: "6: availability on commercially reasonable terms", target: "6: raw materials", fill: "#ffff31"},
{source: "6: raw materials", target: "6: active pharmaceutical ingredients", fill: "#ffff31"},
{source: "6: active pharmaceutical ingredients", target: "6: key ingredients", fill: "#ffff31"},
{source: "6: key ingredients", target: "6: consuming costly", fill: "#ffff31"},
{source: "6: consuming costly", target: "6: numerous factors", fill: "#ffff31"},
{source: "6: numerous factors", target: "6: commercialization", fill: "#ffff31"},
{source: "6: commercialization", target: "6: unanticipated costs", fill: "#ffff31"},
{source: "6: unanticipated costs", target: "6: commercializing generic products may", fill: "#ffff31"},
{source: "6: commercializing generic products may", target: "6: substantially delayed by", fill: "#ffff31"},
{source: "6: substantially delayed by", target: "6: listing with", fill: "#ffff31"},
{source: "6: listing with", target: "6: potentially", fill: "#ffff31"},
{source: "6: potentially", target: "6: such patents", fill: "#ffff31"},
{source: "6: such patents", target: "6: been listed with", fill: "#ffff31"},
{source: "6: been listed with", target: "6: of the FDA ", fill: "#ffff31"},
{source: "6: of the FDA ", target: "6: patent on", fill: "#ffff31"},
{source: "6: patent on", target: "6: branded drug product", fill: "#ffff31"},
{source: "6: branded drug product", target: "6: been litigated", fill: "#ffff31"},
{source: "6: been litigated", target: "6: additional delays", fill: "#ffff31"},
{source: "6: numerous difficulties", target: "14: sales mix", fill: "#79443b"},
{source: "14: sales mix", target: "14: new product introductions", fill: "#79443b"},
{source: "14: new product introductions", target: "14: marketing exclusivity", fill: "#79443b"},
{source: "14: marketing exclusivity", target: "14: on certain new", fill: "#79443b"},
{source: "14: on certain new", target: "14: competition", fill: "#79443b"},
{source: "14: competition", target: "14: certain products", fill: "#79443b"},
{source: "14: certain products", target: "14: availability", fill: "#79443b"},
{source: "14: availability", target: "14: raw materials", fill: "#79443b"},
{source: "14: raw materials", target: "14: products from", fill: "#79443b"},
{source: "14: products from", target: "14: governmental regulatory action", fill: "#79443b"},
{source: "14: governmental regulatory action", target: "14: may involve", fill: "#79443b"},
{source: "14: sales mix", target: "16: branded pharmaceutical companies", fill: "#967bb6"},
{source: "16: branded pharmaceutical companies", target: "16: generics through", fill: "#967bb6"},
{source: "16: generics through", target: "16: legislative", fill: "#967bb6"},
{source: "16: legislative", target: "16: regulatory efforts", fill: "#967bb6"},
{source: "16: regulatory efforts", target: "16: generic products may suffer", fill: "#967bb6"},
{source: "16: branded pharmaceutical companies", target: "17: branded pharmaceutical companies increasingly", fill: "#ed1c24"},
{source: "17: branded pharmaceutical companies increasingly", target: "17: federal legislative", fill: "#ed1c24"},
{source: "17: federal legislative", target: "17: regulatory", fill: "#ed1c24"},
{source: "17: regulatory", target: "17: delay generic competition", fill: "#ed1c24"},
{source: "17: branded pharmaceutical companies increasingly", target: "20: product sales", fill: "#5d8aa8"},
{source: "20: product sales", target: "20: operations", fill: "#5d8aa8"},
{source: "20: operations", target: "20: financial condition", fill: "#5d8aa8"},
{source: "20: financial condition", target: "20: cash flows will suffer", fill: "#5d8aa8"},
{source: "20: product sales", target: "START_HERE", fill: "#5d8aa8"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Free_cash_flow">Free cash flow</a></td>
      <td>In corporate finance, free cash flow (FCF) or free cash flow to firm (FCFF) is the amount by which a business's operating cash flow exceeds its working capital needs and expenditures on fixed assets (known as capital expenditures). It is that portion of cash flow that can be extracted from a company and distributed to creditors and securities holders  without causing issues in its operations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Free_cash_flow_to_equity">Free cash flow to equity</a></td>
      <td>In corporate finance, free cash flow to equity (FCFE) is a metric of how much cash can be distributed to the equity shareholders of the company as dividends or stock buybacks—after all expenses, reinvestments, and debt repayments are taken care of. It is also referred to as the levered free cash flow or the flow to equity (FTE).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cross_product">Cross product</a></td>
      <td>In mathematics, the cross product or vector product (occasionally directed area product, to emphasize its geometric significance) is a binary operation on two vectors in a three-dimensional oriented  Euclidean vector space (named here \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n  ), and is denoted by the symbol \n  \n    \n      \n        ×\n      \n    \n    {\displaystyle \times }\n  . Given two linearly independent vectors a and b, the cross product, a × b (read "a cross b"), is a vector that is perpendicular to both a and b, and thus normal to the plane containing them.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Avon_Products">Avon Products</a></td>
      <td>Avon Products, Inc. or simply known as Avon, is a British multinational cosmetics, skin care, fragrance and personal care company, based in London.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raw_material">Raw material</a></td>
      <td>A raw material, also known as a feedstock, unprocessed material, or primary commodity, is a basic material that is used to produce goods, finished goods, energy, or intermediate materials that are feedstock for future finished products. As feedstock, the term connotes these materials are bottleneck assets and are required to produce other products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Indigenous_materials_in_the_Philippines">Indigenous materials in the Philippines</a></td>
      <td>Indigenous materials are materials that are naturally and locally found in a specific place such as timbers, canes,grass , palms, and rattan. Other indigenous raw materials in the country that are commonly known and used creatively in crafts and decoration are capiz, pearls, corals, and seashells, being an archipelago naturally abundant in beaches and marine resources.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ceramic">Ceramic</a></td>
      <td>A ceramic is any of the various hard, brittle, heat-resistant and corrosion-resistant materials made by shaping and then firing an inorganic, nonmetallic material, such as clay, at a high temperature.  Common examples are earthenware, porcelain, and brick.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Material">Material</a></td>
      <td>Material is a substance or mixture of substances that constitutes an object. Materials can be pure or impure, living or non-living matter.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Recycling">Recycling</a></td>
      <td>Recycling is the process of converting waste materials into new materials and objects. The recovery of energy from waste materials is often included in this concept.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raw_Materials_Research_and_Development_Council">Raw Materials Research and Development Council</a></td>
      <td>The Raw Materials Research and Development Council (RMRDC) is a federal government of Nigerian agency for research institutions that is responsible for industrial raw materials growth, promotion and utilization supervised by Federal Ministry of Sciences and Technology. It has it head office at Maitama district Garki, Abuja.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_elements_facing_shortage">List of elements facing shortage</a></td>
      <td>Since 2011, the European Commission assesses a 3-year list of Critical Raw Materials (CRMs) for the EU economy within its Raw Materials Initiative. To date, 14 CRMs were identified in 2011, 20 in 2014, 27 in 2017 and 30 in 2020.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_trademark">Generic trademark</a></td>
      <td>A generic trademark, also known as a genericized trademark or proprietary eponym, is a trademark or brand name that, because of its popularity or significance, has become the generic term for, or synonymous with, a general class of products or services, usually against the intentions of the trademark's owner.\nA trademark is said to become genericized—or, informally, to have suffered genericide—when it begins as a distinctive product identifier but changes in meaning to become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LANNETT CO INC      ITEM 1A RISK FACTORS     We operate in a rapidly changing <font color="blue">environment</font> that involves a number of     risks,  some of which are beyond our control</td>
    </tr>
    <tr>
      <td>The following discussion     <font color="blue">highlights</font> some of these risks and others are <font color="blue">discussed elsewhere</font> in this     report</td>
    </tr>
    <tr>
      <td>These and other <font color="blue">risks could materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our     business, <font color="blue">financial condition</font>, operating results or <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>RISKS ASSOCIATED WITH INVESTING IN THE BUSINESS OF LANNETT     If we are unable to <font color="blue">successfully</font> develop or <font color="blue">commercialize <font color="blue">new products</font></font>, our     operating results will suffer</td>
    </tr>
    <tr>
      <td>Our future results of <font color="blue"><font color="blue">operations</font> will depend</font> to a <font color="blue"><font color="blue">significant</font> extent upon</font>     our ability to <font color="blue">successfully</font> commercialize new <font color="blue"><font color="blue">generic product</font>s</font> in a timely     manner</td>
    </tr>
    <tr>
      <td>There are <font color="blue">numerous <font color="blue"><font color="blue">difficult</font>ies</font></font> in developing and <font color="blue">commercializing</font>     <font color="blue">new products</font>, including:     •   developing, testing and <font color="blue"><font color="blue">manufacturing</font> products</font> in <font color="blue">compliance with</font>     <font color="blue"><font color="blue">regulatory</font> standards</font> in a timely manner;       •   receiving <font color="blue">requisite <font color="blue"><font color="blue">regulatory</font> approvals</font></font> for <font color="blue">such products</font> in a timely     manner;       •   the <font color="blue">availability</font>, on <font color="blue">commercially</font> reasonable terms, of <font color="blue">raw materials</font>,     including <font color="blue">active <font color="blue">pharmaceutical</font> ingredients</font> and other <font color="blue">key ingredients</font>;       •   developing and <font color="blue">commercializing</font> a new product is time consuming, costly     and subject to <font color="blue">numerous factors</font> that may delay or prevent the successful     <font color="blue">commercialization</font> of <font color="blue">new products</font>;       •   experiencing delays or <font color="blue">unanticipated costs</font>; and       •   <font color="blue">commercializing</font> <font color="blue"><font color="blue">generic product</font>s</font> may be <font color="blue">substantially delayed by</font> the     <font color="blue">listing with</font> the FDA of patents that have the effect of <font color="blue">potentially</font> delaying     approval of the off-patent product by up to 30 months, and in some cases,     <font color="blue">such patents</font> have issued and <font color="blue">been listed with</font> the FDA after the key chemical     <font color="blue">patent on</font> the <font color="blue">branded drug product</font> has expired or <font color="blue">been litigated</font>, causing     <font color="blue"><font color="blue">additional</font> delays</font> in obtaining approval</td>
    </tr>
    <tr>
      <td>As  a  result  of  these and other <font color="blue"><font color="blue">difficult</font>ies</font>, products currently in     <font color="blue"><font color="blue">development</font> by</font> Lannett may or may not receive the <font color="blue"><font color="blue">regulatory</font> approvals</font>     <font color="blue">necessary</font>  for  marketing</td>
    </tr>
    <tr>
      <td>If any of our products, when developed and     approved, cannot be <font color="blue">successfully</font> or <font color="blue">timely commercialized</font>, our operating     results could be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that any investment     we make in developing products will be recouped, even if we are successful     in <font color="blue">commercializing</font> those products</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [46]Table of <font color="blue">Contents       </font>Our gross <font color="blue">profit may fluctuate from period</font> to <font color="blue">period depending upon</font> our     <font color="blue">product <font color="blue">sales mix</font></font>, our <font color="blue">product pricing</font>, and our costs to <font color="blue">manufacture</font> or     <font color="blue">purchase products</font></td>
    </tr>
    <tr>
      <td>Our future results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flows</font> depend     to a <font color="blue"><font color="blue">significant</font> extent upon</font> our <font color="blue">product <font color="blue">sales mix</font></font></td>
    </tr>
    <tr>
      <td>Our sales of products     that we <font color="blue">manufacture</font> tend to create higher gross <font color="blue">margins than</font> do the products     we purchase and resell</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">sales mix</font> will <font color="blue"><font color="blue">significant</font>ly</font> impact     our gross profit from period to period</td>
    </tr>
    <tr>
      <td>Factors that may cause our <font color="blue">sales mix</font>     to vary include:     •   the amount of <font color="blue">new <font color="blue">product introduction</font>s</font>;       •   <font color="blue">marketing exclusivity</font>, if any, which may be obtained <font color="blue">on certain new</font>     products;       •   the level of <font color="blue">competition</font> in the marketplace for <font color="blue">certain products</font>;       •     the <font color="blue">availability</font> of <font color="blue">raw materials</font> and finished <font color="blue">products from</font> our     suppliers; and       •   the scope and outcome of <font color="blue"><font color="blue">government</font>al <font color="blue">regulatory</font> action</font> that <font color="blue">may involve</font>     us</td>
    </tr>
    <tr>
      <td>The <font color="blue">profitability</font> of our <font color="blue">product sales</font> is <font color="blue">also dependent upon</font> the prices we     are able to charge for our products, the costs to <font color="blue">purchase products</font> from     third  parties,  and our ability to <font color="blue">manufacture</font> our products in a cost     <font color="blue">effective manner</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">branded <font color="blue">pharmaceutical</font> companies</font> are successful in limiting the use of     <font color="blue">generics through</font> their <font color="blue">legislative</font> and <font color="blue"><font color="blue">regulatory</font> efforts</font>, our sales of     <font color="blue"><font color="blue"><font color="blue">generic product</font>s</font> may suffer</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">branded <font color="blue">pharmaceutical</font> companies</font> increasingly have used state and     federal <font color="blue">legislative</font> and <font color="blue">regulatory</font> means to delay generic <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>efforts have included:     •   <font color="blue">pursuing new patents</font> for <font color="blue">existing products which may</font> be <font color="blue">granted just</font>     before the expiration of <font color="blue">one patent which could extend patent protection</font> for     <font color="blue"><font color="blue">additional</font> years</font> or <font color="blue">otherwise delay</font> the launch of generics;       •     using  the <font color="blue">Citizen Petition </font>process to <font color="blue">request <font color="blue">amendments</font></font> to FDA     standards;       •   seeking changes to US Pharmacopoeia, an <font color="blue">organization</font> which publishes     industry recognized compendia of drug standards;       •     attaching  patent  extension  <font color="blue">amendments</font>  to non-related federal     <font color="blue">legislation</font>; and       •     engaging in state-by-state <font color="blue">initiatives</font> to enact <font color="blue">legislation</font> that     restricts the <font color="blue">substitution</font> of some <font color="blue">generic drug</font>s, which could have an impact     on products that we are developing</td>
    </tr>
    <tr>
      <td>If <font color="blue">branded <font color="blue">pharmaceutical</font> companies</font> are successful in limiting the use of     <font color="blue"><font color="blue"><font color="blue">generic product</font>s</font> through</font> these or other means, our <font color="blue">sales may decline</font></td>
    </tr>
    <tr>
      <td>If we     experience a material decline in <font color="blue">product sales</font>, our results of <font color="blue">operations</font>,     <font color="blue">financial condition</font> and <font color="blue">cash flows</font> will suffer</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that we infringe their <font color="blue">proprietary rights</font> and may     <font color="blue">prevent us from <font color="blue">manufacturing</font></font> and selling some of our products</td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacture</font>, use and sale of <font color="blue">new products</font> that are the subject of     <font color="blue">conflicting patent rights</font> have been the subject of substantial <font color="blue">litigation</font> in     the <font color="blue"><font color="blue">pharmaceutical</font> industry</font></td>
    </tr>
    <tr>
      <td>These lawsuits relate to the validity and     <font color="blue">infringement</font> of patents or <font color="blue">proprietary rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may have     to <font color="blue">defend against charges</font> that we <font color="blue">violated patents</font> or <font color="blue">proprietary rights</font> of     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>This is <font color="blue">especially</font> true in the case of <font color="blue"><font color="blue"><font color="blue">generic product</font>s</font> on</font>     which the <font color="blue">patent covering</font> the <font color="blue">branded product</font> is expiring, an area where     <font color="blue">infringement</font>  <font color="blue">litigation</font>  is prevalent, and in the case of new branded     products where a <font color="blue">competitor</font> has obtained patents                                         15       _________________________________________________________________    [47]Table of <font color="blue">Contents       </font>for similar products</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be costly and time-consuming, and could     divert the attention of our <font color="blue">management</font> and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>In addition,     if we <font color="blue">infringe on</font> the rights of others, we could lose our right to develop     or <font color="blue">manufacture</font> products or could be required to <font color="blue">pay monetary damages</font> or     royalties to license <font color="blue">proprietary rights</font> from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Although the     parties to patent and intellectual property disputes in the <font color="blue">pharmaceutical</font>     industry have <font color="blue">often settled</font> their <font color="blue">disputes through licensing</font> or similar     <font color="blue">arrangements</font>,  the  costs  associated  with  these <font color="blue">arrangements</font> may be     substantial and could include <font color="blue">ongoing royalties</font></td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be     certain that the <font color="blue">necessary</font> licenses would be available to us on terms we     believe  to  be acceptable</td>
    </tr>
    <tr>
      <td>As a result, an adverse <font color="blue">determination</font> in a     judicial  or  <font color="blue">administrative proceeding</font> or failure to obtain <font color="blue">necessary</font>     licenses could <font color="blue">prevent us from <font color="blue">manufacturing</font></font> and selling a number of our     products, which could harm our business, <font color="blue">financial condition</font>, results of     <font color="blue">operations</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">sufficient supplies from key suppliers</font> that in     some <font color="blue">cases may</font> be the only source of finished products or <font color="blue">raw materials</font>, our     ability to deliver our products to the <font color="blue">market may</font> be impeded</td>
    </tr>
    <tr>
      <td>We are required to identify the supplier(s) of all the <font color="blue">raw materials</font> for our     products in our <font color="blue">application</font>s with the FDA To the extent practicable, we     attempt  to  identify more than one supplier in each drug <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>However, some products and <font color="blue">raw materials</font> are <font color="blue">available only from</font> a single     source and, in some of our drug <font color="blue">application</font>s, only one supplier of products     and <font color="blue">raw materials</font> has been identified, even in instances where multiple     sources exist</td>
    </tr>
    <tr>
      <td>To the extent any <font color="blue"><font color="blue">difficult</font>ies</font> experienced by our suppliers     cannot be resolved within a reasonable time, and at reasonable cost, or if     <font color="blue">raw materials</font> for a <font color="blue">particular product become unavailable from</font> an approved     supplier and we are required to qualify a <font color="blue">new supplier with</font> the FDA, our     <font color="blue">profit margins</font> and market share for the affected product could decrease, as     <font color="blue">well as delay</font> our <font color="blue">development</font> and sales and <font color="blue">marketing efforts</font></td>
    </tr>
    <tr>
      <td>Our policies regarding returns, <font color="blue">allowances</font> and <font color="blue">chargebacks</font>, and marketing     programs adopted by <font color="blue">wholesalers</font>, may reduce our revenues in <font color="blue">future fiscal</font>     periods</td>
    </tr>
    <tr>
      <td>Based on industry practice, <font color="blue">generic drug</font> <font color="blue">manufacture</font>rs have <font color="blue">liberal return</font>     policies  and  have <font color="blue">been willing</font> to give customers post-sale inventory     <font color="blue">allowances</font></td>
    </tr>
    <tr>
      <td>Under  these <font color="blue">arrangements</font>, from time to time, we give our     customers  credits  on our <font color="blue"><font color="blue">generic product</font>s</font> that our customers hold in     inventory after we have decreased the <font color="blue">market prices</font> of the <font color="blue">same generic</font>     <font color="blue">products due</font> to <font color="blue"><font color="blue">competitive</font> pricing</font></td>
    </tr>
    <tr>
      <td>Therefore, if new <font color="blue">competitor</font>s enter the     marketplace and <font color="blue"><font color="blue">significant</font>ly</font> lower the prices of any of their competing     products, we <font color="blue">would likely reduce</font> the price of our product</td>
    </tr>
    <tr>
      <td>As a result, we     would be obligated to provide credits to our customers who are then holding     <font color="blue">inventories</font> of <font color="blue">such products</font>, which could reduce sales revenue and gross     margin for the period the credit is provided</td>
    </tr>
    <tr>
      <td>Like our <font color="blue">competitor</font>s, we also     give credits for <font color="blue">chargebacks</font> to <font color="blue">wholesalers</font> that have <font color="blue">contracts with us</font> for     their sales to hospitals, group purchasing <font color="blue">organization</font>s, pharmacies or     other  customers</td>
    </tr>
    <tr>
      <td>A chargeback is the <font color="blue">difference between</font> the price the     <font color="blue">wholesaler pays</font> and the price that the wholesaler’s end-customer pays for a     product</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">establish reserves <font color="blue">based on</font></font> our prior experience and     our best estimates of the impact that these <font color="blue">policies may</font> have in subsequent     periods, we <font color="blue">cannot ensure</font> that our reserves are adequate or that actual     product returns, <font color="blue">allowances</font> and <font color="blue">chargebacks</font> will not exceed our estimates</td>
    </tr>
    <tr>
      <td>The design, <font color="blue">development</font>, <font color="blue">manufacture</font> and sale of our <font color="blue"><font color="blue">products involve</font>s</font> the     risk of <font color="blue">product liability</font> claims <font color="blue">by consumers</font> and other <font color="blue">third parties</font>, and     <font color="blue">insurance against such potential</font> claims is expensive and may be <font color="blue">difficult</font> to     obtain</td>
    </tr>
    <tr>
      <td>The design, <font color="blue">development</font>, <font color="blue">manufacture</font> and sale of our <font color="blue">products involve</font> an     inherent  risk  of <font color="blue">product liability</font> claims and the <font color="blue">associated adverse</font>     publicity</td>
    </tr>
    <tr>
      <td>Insurance coverage is expensive and may be <font color="blue">difficult</font> to obtain,     and may not be available in the future on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Although we currently maintain <font color="blue">product liability</font> insurance for our products     in amounts we believe to be <font color="blue">commercially</font>                                         16       _________________________________________________________________    [48]Table of <font color="blue">Contents       </font>reasonable, if the <font color="blue">coverage limits</font> of these <font color="blue">insurance policies</font> are not     adequate, a claim <font color="blue">brought against</font> Lannett, <font color="blue">whether covered by insurance</font> or     not,  could have a material adverse effect on our business, results of     <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>Rising insurance costs could negatively impact <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The cost of insurance, including workers compensation, <font color="blue">product liability</font> and     <font color="blue">general liability insurance</font>, have risen in <font color="blue">prior years</font> and may increase in     the future</td>
    </tr>
    <tr>
      <td>In response, we may increase deductibles and/or decrease certain     coverages to mitigate these costs</td>
    </tr>
    <tr>
      <td>These increases, and our <font color="blue">increased risk</font>     due to <font color="blue">increased deductibles</font> and reduced coverages, could have a negative     <font color="blue">impact on</font> our results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>The loss of our <font color="blue"><font color="blue">key personnel</font> could</font> cause our business to suffer</td>
    </tr>
    <tr>
      <td>The  success  of  our  present and future <font color="blue"><font color="blue">operations</font> will depend</font>, to a     <font color="blue">significant</font> extent, upon the experience, <font color="blue">abilities</font> and <font color="blue">continued services</font> of     <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">employment</font> of any of our current <font color="blue">key personnel</font> is     terminated, we <font color="blue">cannot assure</font> you that we will be able to attract and replace     the  <font color="blue">employee with</font> the <font color="blue">same caliber</font> of <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>As such, we have     entered  into  <font color="blue">employment</font>  <font color="blue">agreements with</font> all of our <font color="blue">senior executive</font>     officers</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Significant </font> </font>balances  of  intangible assets, including <font color="blue">product rights</font>     acquired, are subject to <font color="blue">impairment</font> testing and may result in <font color="blue">impairment</font>     charges, which will <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>Our acquired <font color="blue">contractual rights</font> to market and <font color="blue">distribute products</font> are stated     at  cost, less accumulated amortization and related <font color="blue">impairment</font> charges     identified to date</td>
    </tr>
    <tr>
      <td>We determined the <font color="blue">initial cost by referring</font> to the     <font color="blue">original fair value</font> of the <font color="blue">assets exchanged</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">amortization periods</font> for     <font color="blue">product rights</font> are <font color="blue">based on</font> our <font color="blue">assessment</font> of <font color="blue">various factors impacting</font>     estimated <font color="blue">useful lives</font> and <font color="blue">cash flows</font> of the acquired products</td>
    </tr>
    <tr>
      <td>Such factors     include the product’s position in its life cycle, the existence or absence     of like products in the market, various other <font color="blue">competitive</font> and <font color="blue">regulatory</font>     issues and <font color="blue">contr<font color="blue">actual terms</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>changes to any of these factors     would require us to perform an <font color="blue">additional</font> <font color="blue">impairment</font> test on the affected     asset and, if evidence of <font color="blue">impairment</font> exists, we would be required to take an     <font color="blue">impairment</font> charge with respect to the asset</td>
    </tr>
    <tr>
      <td>Such a charge would <font color="blue">adversely</font>     affect our results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>RISKS RELATING TO INVESTING IN THE PHARMACEUTICAL INDUSTRY     Extensive  industry  regulation  has had, and <font color="blue">will continue</font> to have, a     <font color="blue">significant</font> <font color="blue">impact on</font> our business, <font color="blue">especially</font> our product <font color="blue">development</font>,     <font color="blue">manufacturing</font> and <font color="blue">distribution</font> cap<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td>All <font color="blue">pharmaceutical</font> companies, including Lannett, are subject to extensive,     complex,  costly  and  evolving  <font color="blue">regulation by</font> the <font color="blue">federal <font color="blue">government</font></font>,     <font color="blue">principally</font> the FDA and to a <font color="blue">lesser extent by</font> the DEA and state <font color="blue">government</font>     agencies</td>
    </tr>
    <tr>
      <td>The Federal Food, Drug and Cosmetic Act, the Controlled Substances     Act and other <font color="blue">federal statutes</font> and <font color="blue"><font color="blue">regulations</font> govern</font> or influence the     testing, <font color="blue">manufacturing</font>, packing, labeling, storing, record keeping, safety,     approval, advertising, promotion, sale and <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>Under  these <font color="blue">regulations</font>, we are subject to <font color="blue">periodic inspection</font> of our     facilities, procedures and <font color="blue">operations</font> and/or the testing of our <font color="blue">products by</font>     the FDA, the DEA and other authorities, which conduct <font color="blue">periodic inspection</font>s     to confirm that we are in <font color="blue">compliance with</font> all applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In     addition, the FDA conducts pre-approval and post-approval reviews and plant     <font color="blue">inspections</font> to determine whether our systems                                         17       _________________________________________________________________    [49]Table of <font color="blue">Contents       </font>and processes are in <font color="blue">compliance with</font> current Good Manufacturing Practice, or     cGMP, <font color="blue">and other FDA </font><font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Following </font><font color="blue">such <font color="blue">inspections</font></font>, the FDA may     issue notices on Form 483 that could cause us to <font color="blue">modify certain activities</font>     identified during the inspection</td>
    </tr>
    <tr>
      <td>A Form 483 notice is <font color="blue"><font color="blue">generally</font> issued at</font>     the <font color="blue">conclusion</font> of a FDA inspection and <font color="blue">lists conditions</font> the FDA <font color="blue">inspectors</font>     believe <font color="blue">may violate cGMP</font> or other FDA <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>FDA <font color="blue">guidelines specify</font>     that  a  “Warning Letter” is <font color="blue">issued only</font> for violations of “<font color="blue">regulatory</font>     significance” for which the failure to <font color="blue">adequately</font> and promptly achieve     <font color="blue">correction may</font> be expected to result in an <font color="blue">enforcement action</font></td>
    </tr>
    <tr>
      <td>Any such     sanctions, if imposed, <font color="blue">could materially harm</font> our operating results and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Under <font color="blue">certain circumstances</font>, the FDA also has the     authority to <font color="blue">revoke previously granted drug approvals</font></td>
    </tr>
    <tr>
      <td>Similar <font color="blue">sanctions as</font>     detailed above may be available to the FDA under a consent decree, depending     upon the <font color="blue">actual terms</font> of such decree</td>
    </tr>
    <tr>
      <td>Although we have instituted internal     compliance  programs,  if these programs do not meet <font color="blue">regulatory</font> agency     standards or if compliance is deemed deficient in any <font color="blue">significant</font> way, it     <font color="blue">could materially harm</font> our business</td>
    </tr>
    <tr>
      <td>Certain of our vendors are subject to     similar regulation and <font color="blue">periodic inspection</font>s</td>
    </tr>
    <tr>
      <td>The process for obtaining <font color="blue">government</font>al approval to <font color="blue">manufacture</font> and market     <font color="blue">pharmaceutical</font> products is rigorous, time-consuming and costly, and we     <font color="blue">cannot predict</font> the extent to which we may be affected by <font color="blue">legislative</font> and     <font color="blue">regulatory</font>  <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> receiving FDA and other     <font color="blue">government</font>al or third-party approvals prior to <font color="blue">manufacturing</font>, marketing and     shipping our products</td>
    </tr>
    <tr>
      <td>Consequently, there is always the chance that we will     not obtain FDA or other <font color="blue">necessary</font> approvals, or that the rate, timing and     cost of such approvals, will <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">product introduction</font> plans     or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We carry <font color="blue">inventories</font> of certain product(s) in     <font color="blue">anticipation</font>  of  launch,  and if such product(s) are not <font color="blue">subsequently</font>     launched, we may be required to write-off the related inventory</td>
    </tr>
    <tr>
      <td>Federal regulation of <font color="blue">arrangements</font> between <font color="blue">manufacture</font>rs of branded and     <font color="blue"><font color="blue">generic product</font>s</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>As part of the Medicare Prescription Drug, Improvement, and Modernization     Act of 2003, companies are now required to file with the Federal Trade     Commission and the Department of Justice <font color="blue">certain types</font> of <font color="blue">agreements entered</font>     <font color="blue">into between</font> brand and generic <font color="blue">pharmaceutical</font> companies related to the     <font color="blue">manufacture</font>, marketing and sale of <font color="blue">generic versions</font> of <font color="blue">branded drugs</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue"><font color="blue">new requirement</font> could affect</font> the manner in which <font color="blue">generic drug</font> <font color="blue">manufacture</font>rs     resolve intellectual property <font color="blue">litigation</font> and other <font color="blue">disputes with branded</font>     <font color="blue">pharmaceutical</font>  companies and could result <font color="blue">generally</font> in an increase in     private-party <font color="blue">litigation</font> against <font color="blue">pharmaceutical</font> companies or <font color="blue">additional</font>     <font color="blue">investigations</font> or <font color="blue">proceedings by</font> the FTC or other <font color="blue">government</font>al authorities</td>
    </tr>
    <tr>
      <td>The impact of this <font color="blue">new requirement</font> and the potential private-party lawsuits     associated  with  <font color="blue">arrangements</font>  between  brand  name  and <font color="blue">generic drug</font>     <font color="blue">manufacture</font>rs is uncertain, and could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We face strong <font color="blue">competition</font> in our <font color="blue">generic product</font> business</td>
    </tr>
    <tr>
      <td>Revenues and     gross profit derived from the sales of generic <font color="blue">pharmaceutical</font> products tend     to follow a pattern <font color="blue">based on</font> certain <font color="blue">regulatory</font> and <font color="blue">competitive</font> factors</td>
    </tr>
    <tr>
      <td>As     patents for brand <font color="blue">name products</font> and related <font color="blue">exclusivity periods</font> expire, the     first  generic <font color="blue">manufacture</font>r to receive <font color="blue">regulatory</font> approval for generic     <font color="blue">equivalents</font> of <font color="blue">such products</font> is <font color="blue">generally</font> able to achieve <font color="blue">significant</font> market     <font color="blue">penetration</font></td>
    </tr>
    <tr>
      <td>As competing off-patent <font color="blue">manufacture</font>rs receive <font color="blue">regulatory</font>     <font color="blue">approvals on</font> similar products or as brand <font color="blue">manufacture</font>rs launch generic     versions of <font color="blue">such products</font> (for which no separate <font color="blue">regulatory</font> approval is     required), market share, revenues and gross <font color="blue">profit typically decline</font>, in     some <font color="blue">cases dramatically</font></td>
    </tr>
    <tr>
      <td>Accordingly, the level of market share, revenue and     gross  profit <font color="blue">attributable</font> to a particular <font color="blue">generic product</font> is normally     related to the number of <font color="blue">competitor</font>s in that product’s market and the timing     of that product’s <font color="blue">regulatory</font> approval and launch, in relation to competing     approvals  and launches</td>
    </tr>
    <tr>
      <td>Consequently, we <font color="blue">must continue</font> to develop and     introduce <font color="blue">new products</font> in a timely and cost-<font color="blue">effective manner</font> to maintain our     revenues and gross margins</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [50]Table of <font color="blue">Contents       </font>Sales  of  our  products  may continue to be <font color="blue"><font color="blue">adversely</font> affect</font>ed by the     continuing <font color="blue">consolidation</font> of our <font color="blue">distribution</font> network and the <font color="blue">concentration</font>     of our <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal customers</font> are <font color="blue">wholesale drug <font color="blue">distributors</font></font> and <font color="blue">major retail</font>     drug  <font color="blue">store chains</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">customers comprise</font> a <font color="blue">significant</font> part of the     <font color="blue">distribution</font>  network  for  <font color="blue">pharmaceutical</font>  products  in the US <font color="blue">This     </font><font color="blue">distribution</font> network is continuing to undergo <font color="blue">significant</font> <font color="blue">consolidation</font>     marked by mergers and <font color="blue">acquisitions among wholesale <font color="blue">distributors</font></font> and the     growth of large retail drug <font color="blue">store chains</font></td>
    </tr>
    <tr>
      <td>As a result, a small number of     large wholesale <font color="blue">distributors</font> control a <font color="blue">significant</font> share of the market, and     the  number of <font color="blue">independent drug stores</font> and small drug <font color="blue">store chains</font> has     decreased</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">consolidation</font> of drug <font color="blue">wholesalers</font> and retailers     <font color="blue">will increase pricing</font> and other <font color="blue">competitive</font> pressures on drug <font color="blue">manufacture</font>rs,     including Lannett</td>
    </tr>
    <tr>
      <td>For the year ended June 30, 2006, our <font color="blue">three largest customers accounted</font> for     17prca, 15prca and 5prca respectively, of our <font color="blue">net revenues</font></td>
    </tr>
    <tr>
      <td>The loss of any of these     customers  could  materially <font color="blue"><font color="blue">adversely</font> affect</font> our business, results of     <font color="blue">operations</font> and <font color="blue">financial condition</font> and our <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>In addition, the     Company has no long-term supply <font color="blue">agreements with</font> its <font color="blue">customers which would</font>     require them to purchase our products</td>
    </tr>
  </tbody>
</table>